Drug intelligence / Profile preview

B63521^11 gp120 + IHV01 gp120

Development stage
Unknown
Lead developer
GeoVax Labs
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Subcutaneous
01

Overview

B63521^11 gp120 and IHV01 gp120 are recombinant HIV-1 envelope glycoproteins (gp120) developed for use as protein boosts in heterologous prime-boost HIV vaccine regimens. B63521^11 is a monovalent CD4-induced (CD4i) gp120 protein, while IHV01 is a transmitted/founder (T/F) gp120 protein. In the HVTN 132 clinical trial, these proteins are administered alongside the MVA/HIV62B vaccine boost following a GEO-D02 DNA prime. The goal of including these proteins is to enhance the induction of protective antibody responses, particularly those targeting the V1V2 region of the HIV envelope, which has been associated with reduced risk of infection in previous trials like RV144. The development is led by the National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with the Institute of Human Virology and GeoVax.

Other names
gp120 Env proteinsgp-120 Env proteinsgp 120 Env proteinsrecombinant HIV-1 envelope glycoproteins
02

Targets

Env (HIV-1 envelope glycoprotein)

Beyond the preview

Go deeper on B63521^11 gp120 + IHV01 gp120.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on B63521^11 gp120 + IHV01 gp120.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call